Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been assigned an average rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $375.00.
Several brokerages recently issued reports on KRYS. Zacks Research lowered Krystal Biotech from a “hold” rating to a “strong sell” rating in a research note on Friday, October 23rd. Bank of America upped their price target on Krystal Biotech from $392.00 to $400.00 and gave the company a “buy” rating in a report on Monday, September 21st. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a research report on Wednesday, September 23rd. Royal Bank Of Canada reduced their price objective on Krystal Biotech from $400.00 to $375.00 and set an “outperform” rating for the company in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on Krystal Biotech in a report on Thursday, September 24th. They set a “buy” rating and a $441.00 price objective on the stock.
Read Our Latest Report on KRYS
Krystal Biotech Price Performance
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.26. Krystal Biotech had a net margin of 47.91% and a return on equity of 17.02%. The company had revenue of $127.34 million for the quarter, compared to the consensus estimate of $125.77 million. Analysts expect that Krystal Biotech will post 7.74 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 13.10% of the company’s stock.
Institutional Investors Weigh In On Krystal Biotech
Several institutional investors and hedge funds have recently bought and sold shares of the business. Heritage Family Offices LLP bought a new position in shares of Krystal Biotech during the 3rd quarter worth about $25,000. Silvant Capital Management LLC acquired a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $30,000. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the 1st quarter valued at about $34,000. USA Financial Formulas acquired a new stake in shares of Krystal Biotech during the 1st quarter valued at about $44,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Krystal Biotech in the second quarter valued at about $46,000. Institutional investors own 86.29% of the company’s stock.
Krystal Biotech Company Profile
Krystal Biotech, Inc. is a biotechnology company that develops genetic medicines for people with serious diseases. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, the company focuses on treatments that deliver functional genes to patients’ cells. Its commercial product, Vyjuvek (beremagene geperpavec-svdt), is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder. The treatment is designed to help cells produce collagen VII, a protein that supports the skin’s structure.
Featured Stories
- Five stocks we like better than Krystal Biotech
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
